Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Our Impact Parker Institute Researchers Featured at #CICON22 Announcement, Our Impact Latest Pancreatic Cancer Findings Highlighted Announcement, Our Impact #ESMO22 Features Six PICI Network Researchers Announcement, Our Impact Researchers Present at UK Brain Tumour Conference Announcement, Partner Highlight, Press Release Collaboration Speeds Access to Clinical Trial Services Announcement, Our Impact, Press Release Funding the Future of Cancer Research
Announcement, Partner Highlight, Press Release Collaboration Speeds Access to Clinical Trial Services